Background: MET is a potential therapeutic target in advanced HCC; tepotinib is a highly selective MET inhibitor. Here we report final analysis results from a single-arm multicenter phase 2 study investigating the efficacy and safety of tepotinib in pts with sorafenib-treated advanced MET+ HCC (NCT02115373).
No takes yet. Share an insight, caveat, or question.
Decaens et al. (2018) studied this question.